Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Viscosupplements (Nov 2016)

Posted by Matt Breese on Nov 23, 2016

Find me on:

According to our recent payer coverage analysis for viscosupplements, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows that the percentage of commercial restricted lives decreased, while health exchange formularies became more restrictive.


Source: MMIT data as of Q4 2016

Trends:  Recent news related to viscosupplementation shows that treatment alternatives exist for visco prescribers but HCPs are sticking to these treatments overall. The U.S. market continues to grow at a rapid pace with these more costly, but more stable, knee osteoarthritis treatments.

In the full Reality Check on viscosupplements below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on viscosupplements with key findings on clinical characteristics, visco drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing